This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Lymphoseek® Data Presented By Independent Investigators At 8th International Conference On Head And Neck Cancer

Highlights of the Presentations

  • In an oral presentation, “Use of a Novel Receptor-targeted (CD206) Radiotracer, 99m-Tc-Tilmanocept, and SPECT/CT for Sentinel Lymph Node (SLN) Mapping in Head and Neck Squamous Cell Carcinoma (SSCa): Initial Report of Institutional Experience in an Ongoing Phase 3 Study (S146),” Dr. Anna Marcinow of The Ohio State University described the clinical experience with 99m-Tc-tilmanocept in 18 patients. As stated in the abstract, “The data yielded a FNR of 0% and a negative predictive value of 100% using 99m-Tc-tilmanocept in conjunction with SLN mapping and biopsy in the identification of occult metastases.”
  • In a second oral presentation titled, “99m-Tc-Tilmanocept-Identified Sentinel Lymph Nodes Relative to the Pathological Status of Non-Sentinel Lymph Nodes in an Elective Neck Dissection in Cutaneous and Intraoral Head and Neck Squamous Cell Carcinoma: A Single Institutional Experience (S150),” Dr. Stephen Y. Lai, of the University of Texas MD Anderson Cancer Center, described the experience with 99m-Tc-tilmanocept. As stated in the abstract, “Nineteen patients have been enrolled at MD Anderson, and fifteen patients have completed a 30-day follow up at this site which is actively enrolling patients. As all intraoperative 99m-Tc-tilmanocept findings were predictive of the END findings and lead to correct patient staging, the FNR per patients evaluated at this site is 0%. There have been no significant adverse events related to the use of 99m-Tc-tilmanocept.”
  • The clinical experience at the University of Miami was presented in a poster by its author, Dr. Francisco Civantos, titled “Clinical Experience at the University of Miami in a Phase 3 Trial Using Receptor Targeted 99m-Tc-Tilmanocept to Identify and Evaluate the Pathological Status of Sentinel Lymph Nodes (SLNs) vs. Elective Neck Dissection (END) for Patients with Intraoral Squamous Cell Carcinoma.” As stated in the abstract, “At this actively enrolling site, eleven patients have been enrolled. Six patients have undergone SLN mapping and surgery, and completed the study with a 30 day safety follow up. Results showed a 0% per patient FNR, indicating that 99m-Tc-tilmanocept accurately identified those nodes with the highest probability of containing tumor metastases. Additionally, in these patients a negative 99m-Tc-tilmanocept-identified pathology status was 100% predictive of the pathological status of the patient. There have been no significant adverse events related to the use of 99m-Tc-tilmanocept in these patients.”

The results presented at ICHNC are independent results from individual clinical sites participating in NEO3-06 that may or may not be consistent with the complete data that will be available when the trial is completed. The percentage agreement between nodes identified by Lymphoseek and pathology results from a complete neck dissection may decline upon analysis of the data from the completed trial.

2 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,098.45 +18.88 0.11%
S&P 500 2,003.37 +6.63 0.33%
NASDAQ 4,580.2710 +22.5760 0.50%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs